Open-label trial demonstrates safety and symptom improvement in schizophrenia patients switched to a new drug combination, suggesting its potential benefits.
Psychiatrically stable adults with schizophrenia were safely switched from their prior antipsychotic to the combination of xanomeline and trospium chloride, with no new safety issues uncovered, a 52‐week open‐label trial has found. The drug combination also led to improvements on measures of schizophrenia symptom severity. Results of the study were published online Jan. 7, 2026, in Schizophrenia Research .
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: